Myotoxic drugs and immunodeficiency may contribute to the poor outcome of COVID-19 patients with myotonic dystrophy

Detalles Bibliográficos
Autor principal: Finsterer, J.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2020
Materias:
Letter to the Editor
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680670/
https://www.ncbi.nlm.nih.gov/pubmed/33225405
http://dx.doi.org/10.1007/s13760-020-01551-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7680670/
https://www.ncbi.nlm.nih.gov/pubmed/33225405
http://dx.doi.org/10.1007/s13760-020-01551-8

Ejemplares similares